

NYP CB (8046.TW)

New CAPEX plan on high-end CoPoS substrates, suggesting a solid LT ASP uptrend; GM trend start outpacing other ABF players; Re-iterate Buy (on CL)

8046.TW 12m Price Target: NT\$2,500.00 Price: NT\$1,105.00 Upside: 126.2%

2Q26 result overview

NYP CB 2Q26 core business (OPI) was 15% higher than BBG consensus, but was 8% lower than our estimate (most bullish on the street). **GM went up by 8.9ppt QoQ, the highest growth among all Taiwan ABF players (Unimicron/Kinsus' GM went up by +6.8ppt/+4.9ppt QoQ only in 2Q26)**, which is in-line with our more bullish view on spot price ABF substrates players' profitability expansion speed vs. LTA players. For earnings, NYP CB's 2Q EPS was 5% higher than the BBG consensus but was 18% lower than GSe.

3Q26 outlook - UTR in Kunshan start ramping up despite low yield rate, while ABF/BT pricing hike will continue to drive GM/OPM
For 3Q26, we expect NYP CB's revenue will go up by 27% QoQ in 3Q26, while the key update is the company's Kunshan plant (~15-20% of overall ABF substrate capacity) utilization rate reached 70% in July (vs. 50% in 2Q26; which drove July revenue went up by 16% MoM), with key high end customers starting to place orders in mainland China (which is in-line with our view that all the ABF substrates capacity will be working under fully utilized level from 2H26, due to the severe shortage condition of ~15-20% shortage ratio; see [here](#)).

However, our understanding is that the company's Kunshan plant was built for mid to low end ABF substrates, and the increasing production on high-end ABF substrate in Kunshan plant could lead to an unfavorable GM for overall ABF substrates business in the near term (3Q26), but we do expect this will be offset by the increasing spot price from August/September, and we also believe the yield rate will eventually improve and lead to an even higher than company's average GM in coming months/quarters. **As a result, we expect NYP CB's 3Q GM will further jump by 6.6ppt QoQ to 31.3%, whose GM could surpass Kinsus/Unimicron and become the highest among all Taiwan ABF suppliers (we expect**

BUY (CL)

Chao Wang

+886(2)2730-4195 | kuan-chao.wang@gs.com
Goldman Sachs (Asia) L.L.C., Taipei Branch

Allen Chang

+852-2978-2930 | allen.k.chang@gs.com
Goldman Sachs (Asia) L.L.C.

Al Wang

+886(2)2730-4081 | al.wang@gs.com
Goldman Sachs (Asia) L.L.C., Taipei Branch


Key Data

Market cap: NT\$714.0bn / \$22.1bn
Enterprise value: NT\$697.3bn / \$21.6bn
3m ADTV: NT\$17.1bn / \$536.2mn
Taiwan
Taiwan Electronic Components
M&A Rank: 3
Leases incl. in net debt & EV?: No

GS Forecast

	12/25	12/26E	12/27E	12/28E
Revenue (NT\$ mn) New	40,173.0	63,496.6	128,352.1	208,109.8
Revenue (NT\$ mn) Old	40,173.0	64,805.0	127,360.9	194,486.1
EBITDA (NT\$ mn)	8,876.3	23,683.3	61,326.0	107,543.3
EPS (NT\$) New	3.01	20.68	65.83	120.18
EPS (NT\$) Old	3.01	22.41	64.66	110.17
P/E (X)	56.6	53.4	16.8	9.2
P/B (X)	2.4	13.2	9.0	5.7
Dividend yield (%)	1.2	0.7	2.4	4.4
CROCI (%)	6.3	20.0	43.1	60.2
	6/26	9/26E	12/26E	3/27E
EPS (NT\$)	3.50	6.16	8.99	11.23

GS Factor Profile



Source: Company data, Goldman Sachs Research estimates.
See disclosures for details.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

BUY CL

NYPCB (8046.TW)


Rating since Aug 25, 2025

Ratios & Valuation

	12/25	12/26E	12/27E	12/28E
P/E (X)	56.6	53.4	16.8	9.2
P/B (X)	2.4	13.2	9.0	5.7
FCF yield (%)	0.5	1.3	2.6	5.6
EV/EBITDAR (X)	11.4	29.4	11.2	6.1
EV/EBITDA (excl. leases) (X)	11.4	29.4	11.2	6.1
CROCI (%)	6.3	20.0	43.1	60.2
ROE (%)	4.3	26.7	63.6	75.4
Net debt/equity (%)	(18.6)	(30.8)	(37.6)	(42.1)
Net debt/equity (excl. leases) (%)	(18.6)	(30.8)	(37.6)	(42.1)
Interest cover (X)	27,921.3	—	—	—
Days inventory outst, sales	41.7	32.4	22.7	21.1
Receivable days	76.4	70.4	63.5	68.7
Days payable outstanding	16.1	21.9	24.5	25.3
DuPont ROE (%)	4.2	24.7	53.4	61.5
Turnover (X)	0.7	0.8	1.1	1.2
Leverage (X)	1.3	1.4	1.4	1.4
Gross cash invested (ex cash) (NT\$)	98,759.1	105,904.3	125,787.2	157,104.7
Average capital employed (NT\$)	37,251.5	37,486.7	43,581.2	61,391.0
BVPS (NT\$)	71.38	83.79	123.28	195.39

Growth & Margins (%)

	12/25	12/26E	12/27E	12/28E
Total revenue growth	24.4	58.1	102.1	62.1
EBITDA growth	70.9	166.8	158.9	75.4
EPS growth	855.6	586.4	218.3	82.6
DPS growth	100.0	313.6	218.3	82.6
EBIT margin	4.9	25.9	41.9	47.8
EBITDA margin	22.1	37.3	47.8	51.7
Net income margin	4.8	21.0	33.1	37.3

Price Performance**Income Statement (NT\$ mn)**

	12/25	12/26E	12/27E	12/28E
Total revenue	40,173.0	63,496.6	128,352.1	208,109.8
Cost of goods sold	(36,525.9)	(45,172.0)	(71,625.7)	(104,343.1)
SG&A	(1,664.6)	(1,212.8)	(1,833.5)	(2,593.7)
R&D	0.0	(666.9)	(1,167.4)	(1,610.1)
Other operating inc./exp.)	—	—	—	—
EBITDA	8,876.3	23,683.3	61,326.0	107,543.3
Depreciation & amortization	(6,893.8)	(7,238.5)	(7,600.5)	(7,980.5)
EBIT	1,982.4	16,444.8	53,725.5	99,562.8
Net interest inc./exp.)	158.2	160.3	311.6	558.6
Income/(loss) from associates	0.0	0.0	0.0	—
Pre-tax profit	2,345.5	17,127.0	53,725.5	99,562.8
Provision for taxes	(398.7)	(3,765.1)	(11,189.0)	(21,903.8)
Minority interest	—	—	—	—
Preferred dividends	—	—	—	—
Net inc. (pre-exceptionals)	1,946.8	13,361.9	42,536.5	77,659.0
Post-tax exceptionals	—	—	—	—
Net inc. (post-exceptionals)	1,946.8	13,361.9	42,536.5	77,659.0
EPS (basic, pre-exception) (NT\$)	3.01	20.68	65.83	120.18
EPS (diluted, pre-exception) (NT\$)	3.01	20.68	65.83	120.18
EPS (basic, post-exception) (NT\$)	3.01	20.68	65.83	120.18
EPS (diluted, post-exception) (NT\$)	3.01	20.68	65.83	120.18
DPS (NT\$)	2.00	8.27	26.33	48.07
Div. payout ratio (%)	66.4	40.0	40.0	40.0

Balance Sheet (NT\$ mn)

	12/25	12/26E	12/27E	12/28E
Cash & cash equivalents	8,589.5	16,700.0	29,939.4	53,197.8
Accounts receivable	9,707.7	14,786.9	29,890.2	48,463.9
Inventory	5,067.7	6,188.0	9,811.7	14,293.6
Other current assets	257.8	257.8	257.8	257.8
Total current assets	23,622.6	37,932.6	69,899.1	116,213.1
Net PP&E	35,373.3	35,134.8	42,534.3	59,553.9
Net intangibles	—	—	—	—
Total investments	500.2	500.2	500.2	500.2
Other long-term assets	1,711.2	1,711.2	1,711.2	1,711.2
Total assets	61,207.4	75,278.8	114,644.9	177,978.4
Accounts payable	1,710.9	3,712.8	5,887.0	8,576.1
Short-term debt	0.0	—	—	—
Short-term lease liabilities	—	—	—	—
Other current liabilities	5,477.9	9,530.3	21,200.2	35,249.2
Total current liabilities	7,188.8	13,243.1	27,087.2	43,825.3
Long-term debt	0.0	—	—	—
Long-term lease liabilities	—	—	—	—
Other long-term liabilities	7,895.8	7,895.8	7,895.8	7,895.8
Total long-term liabilities	7,895.8	7,895.8	7,895.8	7,895.8
Total liabilities	15,084.5	21,138.8	34,982.9	51,721.1
Preferred shares	—	—	—	—
Total common equity	46,122.9	54,140.0	79,661.9	126,257.3
Minority interest	—	—	—	—
Total liabilities & equity	61,207.4	75,278.8	114,644.9	177,978.4
Net debt, adjusted	(8,589.5)	(16,700.0)	(29,939.4)	(53,197.8)

Cash Flow (NT\$ mn)

	12/25	12/26E	12/27E	12/28E
Net income	1,946.8	13,361.9	42,536.5	77,659.0
D&A add-back	6,893.8	7,238.5	7,600.5	7,980.5
Minority interest add-back	—	—	—	—
Net (inc)/dec working capital	(3,218.0)	(4,197.5)	(16,552.8)	(20,366.5)
Other operating cash flow	(2,595.6)	0.0	0.0	0.0
Cash flow from operations	3,027.0	16,402.9	33,584.1	65,273.0
Capital expenditures	(2,422.3)	(7,000.0)	(15,000.0)	(25,000.0)
Acquisitions	—	—	—	—
Divestitures	74.6	—	—	—
Others	625.1	—	—	—
Cash flow from investing	(1,722.7)	(7,000.0)	(15,000.0)	(25,000.0)
Repayment of lease liabilities	—	—	—	—
Dividends paid (common & pref)	(646.2)	(1,292.3)	(5,344.7)	(17,014.6)
Inc/(dec) in debt	—	—	—	—
Other financing cash flows	(549.4)	0.0	0.0	0.0
Cash flow from financing	(1,195.5)	(1,292.3)	(5,344.7)	(17,014.6)
Total cash flow	108.8	8,110.5	13,239.4	23,258.4
Free cash flow	604.7	9,402.9	18,584.1	40,273.0

Source: Company data, Goldman Sachs Research estimates.

Kinsus/Unimicron GM will reach 28.4%/27.4% in 3Q).**Investment thesis - GM to surpass TW peers from 2H26; new CAPEX on high end ABF substrates suggesting more upside on ASP in LT**

As discussed several times (see [here](#)), we believe NYPCB will start outgrowing players on the margin side from 2H26, when the ABF substrate market enters a real supply shortage stage, and we saw NYPCB's GM approaching Kinsus/Unimicron's in 2Q26, who should start delivering a stronger GM from 2H26, as we discussed, due mainly to the company's proactive strategy on pricing (focus on spot price market should make the company deliver a better GM/OPM outlook than LTA peers during the shortage period). Considering our positive view on the ABF substrate demand and the long capacity expansion lead time of the industry, we believe the ABF substrate capacity shortage period will last for 30+ months, implying NYPCB's outperformance on GM/OPM growth vs. other TW ABF names should not be just a short-term condition.

Moreover, the company announced a new CAPEX plan ([here](#)), while the company will invest in NT\$46.8bn (vs. the company's overall CAPEX in 2025 was only at NT\$2.4bn vs. peak annual CAPEX in last upcycle was NT\$16.9bn only) on a new high-end ABF substrate plant in Chiayi. Based on our estimate, the new capacity will be used to produce TSMC next generation CoPoS packaging substrates, and the capacity could come on stream right after TSMC start mass producing CoPoS packaging technology in 2H28-1H29 (the capacity expansion lead time is also in-line with our view of 30+ months). We do believe the company's proactive investment in the next generation packaging technology should lead the company's overall ASP to another level, while we believe the substrate size / layer count could be 100%/ 30%+ larger/higher than the company's most high end products now, suggesting a long term revenue/earnings outlook after 2028.

Overall, considering the near term profitability outperformance and the positive long term revenue/earning outlook with the new high-end capacity expansion, we maintain our Buy rating (on CL) on NYPCB with new TP of NT\$2,500 (from NT\$2,310).

Exhibit 1: 2Q26 result comp table

NYPCB (8046.TW)	2Q26			QoQ		YoY		Bloomberg consensus	
P&L (NT\$m)	Actual	GS est.	Diff (%)	1Q26	QoQ	2Q25	YoY	Consensus	%
Revenue	13,575	13,575	0%	11,177	21%	9,583	42%	13,475	1%
Gross profits	3,360	3,568	-6%	1,771	90%	769	337%	2,887	16%
Operating profits	2,899	3,144	-8%	1,352	114%	366	692%	2,524	15%
Pre-tax income	2,976	3,444	-14%	1,598	86%	(227)	-1413%	2,566	16%
Net earnings	2,262	2,755	-18%	1,309	73%	(187)	-1307%	2,174	4%
EPS, NT\$	3.50	4.26	-18%	2.03	73%	(0.29)	-1308%	3.35	5%
Gross margin (%)	24.7%	26.3%	-1.5ppt	15.8%	8.9ppt	8.0%	16.7ppt	21.4%	3.3ppt
EBIT margin (%)	21.4%	23.2%	-1.8ppt	12.1%	9.3ppt	3.8%	17.5ppt	18.7%	2.6ppt
Net margin (%)	16.7%	20.3%	-3.6ppt	11.7%	5.0ppt	-2.0%	18.6ppt	16.1%	0.5ppt

Source: Company data, Goldman Sachs Global Investment Research, Bloomberg

Earnings revision

We revise up our 2027/28/29E earnings estimate by 2/9/23% to factor in the more

favorable than expected ABF GM outlook in coming years considering the more increased tightness on the ABF substrate industry. Moreover, the company's new announcement on capacity build for high layer count / large body size substrate should lead to an even more favorable product mix and shipment from 2H28.

We slightly revise down the 2026 revenue estimate by 2% (due to the less favorable than expected PCB demand) and revise down our GM assumption by 1.0ppt (to factor in the slower than expected initial Kunshan plant ABF substrate yield rate ramp up on high-end products).

Exhibit 2: Earnings revision table

NYPCB P&L (NT\$ mn)	2026E New	2026E Old	Diff.	2027E New	2027E Old	Diff.	2028E New	2028E Old	Diff.	2029E New	2029E Old	Diff.
Sales	63,497	64,805	-2%	128,352	127,361	1%	208,110	194,486	7%	336,653	295,639	14%
Gross Profit	18,325	19,351	-5%	56,726	55,812	2%	103,767	95,782	8%	189,175	155,062	22%
EBIT	16,445	17,488	-6%	53,725	52,764	2%	99,563	91,270	9%	181,906	148,104	23%
Net Income	13,362	14,478	-8%	42,537	41,783	2%	77,659	71,191	9%	142,836	116,387	23%
EPS (NT\$)	20.68	22.41	-8%	65.83	64.66	2%	120.18	110.17	9%	221.05	180.12	23%
Ratio analysis												
Gross margin	28.9%	29.9%	-1.0pp	44.2%	43.8%	0.4pp	49.9%	49.2%	0.6pp	56.2%	52.4%	3.7pp
EBIT margin	25.9%	27.0%	-1.1pp	41.9%	41.4%	0.4pp	47.8%	46.9%	0.9pp	54.0%	50.1%	3.9pp
Net margin	21.0%	22.3%	-1.3pp	33.1%	32.8%	0.3pp	37.3%	36.6%	0.7pp	42.4%	39.4%	3.1pp

Source: Goldman Sachs Global Investment Research

Valuation

We are Buy rated on NYPCB, with a new TP of NT\$2,500 (from NT\$2,310), based on an unchanged 21x 2028E EPS (+1.5x STDV above the past upcycle average P/E of 13.3x as we expect a better pricing outlook in spot price market this time vs. last upcycle in 2020-2022), considering the much better customer mix and the much better demand visibility.

Exhibit 3: NYPCB P&L table

NT\$m	1Q26	2Q26	3Q26E	4Q26E	1Q27E	2Q27E	3Q27E	4Q27E	1Q28E	2Q28E	3Q28E	4Q28E	2025	2026E	2027E	2028E	2029E
Revenue	11,177	13,575	17,284	21,460	24,118	29,222	34,661	40,351	44,585	50,594	53,276	59,655	40,173	63,497	128,352	208,110	336,653
Gross profit	1,771	3,360	5,408	7,785	9,566	12,422	15,716	19,022	21,749	25,020	26,462	30,536	3,647	18,325	56,726	103,767	189,175
Operating expense	(419)	(460)	(486)	(514)	(607)	(696)	(769)	(928)	(951)	(961)	(1,012)	(1,279)	(1,665)	(1,880)	(3,001)	(4,204)	(7,269)
Operating income	1,352	2,899	4,922	7,271	8,959	11,726	14,947	18,094	20,798	24,059	25,450	29,257	1,982	16,445	53,725	99,563	181,906
Pretax income	1,598	2,976	5,102	7,451	8,959	11,726	14,947	18,094	20,798	24,059	25,450	29,257	2,346	17,127	53,725	99,563	182,626
Taxes expense	(290)	(714)	(1,122)	(1,639)	(1,702)	(2,580)	(3,288)	(3,619)	(4,575)	(5,293)	(5,599)	(6,436)	(399)	(3,765)	(11,189)	(21,904)	(39,790)
Net income	1,309	2,262	3,979	5,812	7,256	9,146	11,659	14,475	16,222	18,766	19,851	22,820	1,947	13,362	42,537	77,659	142,836
EPS, NT\$	2.03	3.50	6.16	8.99	11.23	14.15	18.04	22.40	25.11	29.04	30.72	35.32	3.01	20.68	65.83	120.18	221.05
Ratio analysis and assumption																	
As % of sales																	
Gross margin	15.8%	24.7%	31.3%	36.3%	39.7%	42.5%	45.3%	47.1%	48.8%	49.5%	49.7%	51.2%	9.1%	28.9%	44.2%	49.9%	56.2%
Operating expense ratio	3.8%	3.4%	2.8%	2.4%	2.5%	2.4%	2.2%	2.3%	2.1%	1.9%	1.9%	2.1%	4.1%	3.0%	2.3%	2.0%	2.2%
Operating margin	12.1%	21.4%	28.5%	33.9%	37.1%	40.1%	43.1%	44.8%	46.6%	47.6%	47.8%	49.0%	4.9%	25.9%	41.9%	47.8%	54.0%
Net margin	11.7%	16.7%	23.0%	27.1%	30.1%	31.3%	33.6%	35.9%	36.4%	37.1%	37.3%	38.3%	4.8%	21.0%	33.1%	37.3%	42.4%
QoQ growth (%)																	
Revenue	0.1%	21.5%	27.3%	24.2%	12.4%	21.2%	18.6%	16.4%	10.5%	13.5%	5.3%	12.0%	-	-	-	-	-
Gross profit	26.7%	89.7%	61.0%	44.0%	22.9%	29.9%	26.5%	21.0%	14.3%	15.0%	5.8%	15.4%	-	-	-	-	-
Operating income	40.4%	114.4%	69.8%	47.7%	23.2%	30.9%	27.5%	21.1%	14.9%	15.7%	5.8%	15.0%	-	-	-	-	-
Net income	8.9%	72.8%	75.9%	46.1%	24.9%	26.0%	27.5%	24.2%	12.1%	15.7%	5.8%	15.0%	-	-	-	-	-
YoY growth (%)																	
Revenue	32.1%	41.7%	57.6%	92.2%	115.8%	115.3%	100.5%	88.0%	84.9%	73.1%	53.7%	47.8%	24%	58%	102%	62%	62%
Gross profit	311.7%	337.0%	415.2%	456.8%	440.0%	269.8%	190.6%	144.3%	127.4%	101.4%	68.4%	60.5%	920%	402%	210%	83%	82%
Operating income	3986.2%	692.0%	693.5%	655.1%	562.5%	304.4%	203.7%	148.8%	132.2%	105.2%	70.3%	61.7%	-257%	730%	227%	85%	83%
Net income	530.8%	-1306.7%	449.0%	383.6%	454.5%	304.4%	193.0%	149.1%	123.6%	105.2%	70.3%	57.7%	856%	586%	218%	83%	84%

Source: Company data, Goldman Sachs Global Investment Research

Investment Thesis & PT methodology and risks

Investment Thesis - NYPCB

NYPCB manufactures and markets printed circuit boards (PCBs) and integrated circuit (IC) substrates (including ABF and BT substrates). We are Buy-rated on NYPCB considering the company's high exposure to BT substrates and non-LTA ABF substrate

(70%+ of total revenue), where we expect GM/OPM to increase significantly in the coming quarters (from breakeven in OPM in 1H25 to 27/41% in 2026/27E) due to the favorable substrate pricing outlook. Despite the company's low exposure to high-end ABF substrate industry (<20% of total revenue in 1H25), we believe the expanding demand from ASIC AI server and high-end switch IC demand will drive the company's high-end ABF revenue exposure to 40%+ by 2027E, suggesting better GM/OPM outlook in the long term. In 2H25-2H26, we believe NYPCB will continue to benefit from stronger ABF/BT pricing and should be a key beneficiary of the pricing uptrend considering the company's key focus on BT and non-LTA ABF substrate industries. Moreover, in the long term (after 2026), we expect the ABF industry to return to supply tightness, and NYPCB's expanding high-end exposure will lead to a long term earnings growth outlook (122% 2026-28E earnings CAGR). As a result, we see solid upside potential for NYPCB's earnings and stock performance.

Price Target Risks and Methodology - NYPCB

Valuation methodology: Our 12-month target price of NT\$2,500 for NYPCB is based on 21x 2028E P/E, which is +1.5x STDV higher than the past upcycle average P/E (13.3x).

Key downside risks: (1) Slower-than-expected PC demand recovery, (2) Slower-than-expected ABF substrates pricing upgrading outlook, and (3) Slower-than-expected NYPCB new high-end capacity qualification progress.

Disclosure Appendix

Reg AC

I, Chao Wang, hereby certify that all of the views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Chao Wang Goldman Sachs (Asia) L.L.C., Taipei Branch, Allen Chang Goldman Sachs (Asia) L.L.C., Al Wang Goldman Sachs (Asia) L.L.C., Taipei Branch.

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for NYPCB is/are relative to the other companies in its/their coverage universe: AWSC, Airtac International Group, Co-Tech Development Corp., Delta Electronics, Elite Material, GCE, Hiwin Corp., ITEQ Corp, Kinsus, Lotes, NYPCB, Taiwan Union Technology Corp., Unimicron Technology, Win Semiconductors Corp., Yageo Corp., Zhen Ding Technology Holding

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs beneficially owned 1% or more of common equity (excluding positions managed by affiliates and business units not required to be aggregated under US securities law) as of the second most recent month end: NYPCB (NT\$1,105.00)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: NYPCB (NT\$1,105.00)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: NYPCB (NT\$1,105.00)

Goldman Sachs had a non-securities services client relationship during the past 12 months with: NYPCB (NT\$1,105.00)


Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution				Investment Banking Relationships		
	Buy	Hold	Sell		Buy	Hold	Sell
Global	50%	34%	16%		65%	59%	43%

As of July 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,104 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)



Target price history table(s)
NYPCB (8046.TW)

Date of report	Target price (NT\$)	Closing price (NT\$)
12-Jul-26	2,310.00	1,215.00
07-May-26	1,115.00	947.00
21-Apr-26	970.00	789.00
08-Apr-26	850.00	637.00
25-Feb-26	750.00	553.00
03-Feb-26	655.00	394.50
05-Nov-25	340.00	272.00
21-Oct-25	330.00	273.50
22-Sep-25	310.00	235.50
25-Aug-25	280.00	186.00
07-Aug-25	125.00	172.50
04-Jul-25	110.00	126.00
29-Apr-25	98.00	101.00
28-Feb-25	128.00	136.00
06-Nov-24	130.00	124.50
18-Oct-24	143.00	133.50
07-Aug-24	168.00	143.00
16-Jul-24	195.00	183.50
06-May-24	210.00	185.00
03-Apr-24	230.00	209.00
01-Mar-24	210.00	210.50
29-Nov-23	240.00	251.00
03-Nov-23	280.00	232.50
16-Oct-23	300.00	253.00

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenue. **or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from being an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be a U.S. person and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communication with the company, public appearances and trading in securities covered by the analysts.



Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for “wholesale clients” within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client’s objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client’s own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs’ Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst – SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details, a copy of the annual compliance audit report and other relevant information and disclosures can be found at this link: <https://www.goldmansachs.com/worldwide/india/research-analyst>. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for “professional investors” within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither “registered banks” nor “deposit takers” (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for “wholesale clients” (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom’s departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock’s total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region’s Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts’ investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or

policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all

research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.